Logo Image
Feature|Videos|May 21, 2026

Evolving to Meet Today's Pharmaceutical Demand

Key Takeaways

  • Describe how private equity-driven consolidation has restructured the CDMO landscape for oral solid dose pharmaceuticals over the past decade.
  • Identify the strategic rationale behind Coating Place's partnership with 1315 Capital and how the investment is being used to expand capacity and address customer pain points.
SHOW MORE

Ajay Damani, President of Coating Place, discusses the impact of the current CDMO landscape on oral solid dose pharmaceuticals.

Sponsored by Coating Place

Ajay Damani, President of Coating Place, sat down with Pharmaceutical Technology to discuss the private equity shift within the CDMO landscape and what that means for oral solid dose pharmaceuticals. Ultimately, this consolidation has left behind a market of niche specialists and large integrated providers. Coating Place is working to solve a key problem which is the lack of a fully integrated packaging solution. To fuel this growth, Coating Place has partnered with 1315 Capital, a Philadelphia-based Life Sciences growth equity firm that brings both financial backing and strategic leadership to the organization. Founded 50 years ago, Coating Place has built its reputation on fluid bed coating expertise spanning pharmaceuticals, nutraceuticals, and animal health. They are committed to preserving its collaborative, entrepreneurial culture throughout its expansion. Damani emphasizes that current and prospective partners can expect continued investment in quality systems, project management, supply chain capabilities, and key talent development as the company enters its next phase of growth.

Related Content